Back
11 August 2026
The ITA reports that Mongolian wrestler Erdenesuvd Bat Erdene has been sanctioned with a two-year period of ineligibility after testing positive for furosemide following an out-of-competition doping control on 21 September 2023.
Furosemide is prohibited under the WADA Prohibited List as S5. Diuretics and Masking Agents. It is prohibited at all times (in- and out-of-competition) and is classified as a specified substance. Furosemide can be used by athletes to excrete water for rapid weight loss.
The athlete’s sample of 21 September 2023 initially returned an Atypical Finding (ATF)¹ for furosemide. As required by the WADA stakeholder notice regarding potential diuretic contamination cases (WADA Stakeholder Notice)², the ITA initiated an investigation to determine whether or not the ATF was caused by inadvertent contamination from a pharmaceutical product taken by the athlete prior to sample collection. However, the athlete was unable to establish that the ATF was a result of pharmaceutical contamination, and therefore the ATF was pursued as an Adverse Analytical Finding³, and subsequently as an ADRV under Articles 2.1 (presence of a prohibited substance) and 2.2 (use of a prohibited substance or a prohibited method) of the UWW Anti-Doping Rules (UWW ADR).
The sanction was issued by the ITA on behalf of UWW in accordance with article 8.3.3 of the UWW ADR (and equivalent provision in the World Anti-Doping Code).⁴ The period of ineligibility is effective from 4 August 2026 until 3 August 2028 and the athlete’s results have been disqualified from 21 September 2023 onwards.
Parties with a right of appeal may challenge the decision before the appeals division of the Court of Arbitration for Sport (CAS) in accordance with article 13.2 of the UWW ADR.
The ITA will not comment further on this case.
¹ A report from a WADA-accredited laboratory which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an Adverse Analytical Finding.
² The WADA Stakeholder Notice is available at: https://www.wada-ama.org/sites/default/files/resources/files/stakeholder_notice_regarding_contamination_with_certain_diuretics_final_1_june_2021.pdf
³ A report from a WADA-accredited laboratory that, consistent with the International Standard for Laboratories, establishes in a sample the presence of a prohibited substance or its metabolites or markers or evidence of the use of a prohibited method.
⁴ When an athlete does not challenge the assertion of an ADRV and does not request a hearing, anti-doping organisations have the possibility to issue a written decision sanctioning the athlete and imposing the applicable consequences without having to refer the case to a hearing panel. This is provided in articles 8.3.2 and 8.3.3 of the UWW Anti-Doping Rules and article 8.3 of the World Anti-Doping Code.
